VNX-205

VNX-205 is an investigational AAV-delivered T-cell immuno-gene therapy being developed by Vironexis Biotherapeutics for the treatment of prostate cancer. Utilizing the proprietary TransJoin™ platform, VNX-205 employs an adeno-associated virus (AAV) vector to deliver a genetic payload that enables the *in vivo* production of therapeutic proteins designed to program the patient's endogenous T cells to recognize and eliminate prostate cancer cells. This approach aims to provide the benefits of T-cell-mediated immunotherapy, such as those seen with CAR-T or bispecific T-cell engagers, through a single administration of gene therapy, potentially overcoming the logistical and manufacturing challenges associated with traditional ex vivo cell therapies.